SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16: 15691583.
  • 2
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Panel conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001; 93: 979989.
  • 3
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 16871717.
  • 4
    Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC trial: efficacy an safety update analysis. Cancer. 2003; 98: 18021810.
  • 5
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 27472757.
  • 6
    Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005; 23: 51385147.
  • 7
    Coombes RC, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 8
    Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: a randomized trial in post-menopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen. Updated survival analysis. Breast Cancer Res Treat. 2004; 88: 57. Abstract 3.
  • 9
    Jakesz R, Jonat W, Gnant M, et al. Switching of post-menopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455462.
  • 10
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy of early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 11
    Coombes RC, Paridaens R, Jassem J, et al. First mature analysis of the Intergroup Exemestane Study. ASCO Annual Meeting Proc Part I. 2006; 24(18S). Abstract LBA527.
  • 12
    Kaufmann M, Jonat W, Hilfrich J, et al. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. ASCO Annual Meeting Proc Part I. 2006; 24(18S). Abstract 547.
  • 13
    Robert NJ, Goss PE, Ingle JN, et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. ASCO Annual Meeting Proc Part I. 2006; 24(18S). Abstract 550.
  • 14
    Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol. 2001; 19: 42094215.
  • 15
    Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol Suppl. 2006; 7: vii10vii14.
  • 16
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 18
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 19
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 20
    Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994; 86: 15341539.
  • 21
    Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005; 103: 11141121.
  • 22
    Shapira DV, Kumar NB, Lyman PA, et al. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat. 1990; 17: 37.
  • 23
    Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992; 305: 225226.
  • 24
    Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7: 991996.
  • 25
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619629.